Dr Gillian Tomlinson
BSc (Hons), MBChB, FRCP, PhD
Clinical Medicine, School of Medicine and Population Health
Senior Lecturer in Respiratory Medicine
Honorary Consultant in Respiratory Medicine
+44 114 215 9557
Full contact details
Clinical Medicine, School of Medicine and Population Health
Room LU115, L Floor
The Medical School
Beech Hill Road
91直播
S10 2RX
- Profile
-
For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk
I joined the University of 91直播 as a Senior Lecturer in Respiratory Medicine in 2024. I also undertake clinical duties as a consultant in Respiratory Medicine and Acute Medicine, with a specialist interest in respiratory infection, particularly tuberculosis (TB) and interstitial lung disease.
I hold a medical degree from Edinburgh University and undertook postgraduate training in general medicine in Glasgow and London. I began my specialist training in respiratory medicine in Glasgow. I subsequently undertook a Medical Research Council (MRC) Clinical Research Training Fellowship using genome wide molecular profiling to understand inflammatory processes in respiratory disease, leading to the award of a PhD in Immunology at University College London. I then extended my expertise in transcriptional profiling to tissue samples from the site of disease within my NIHR Academic Clinical Lecturer post at UCL. This work led to discovery and validation of clinically translatable signatures with the potential to improve diagnostic accuracy and patient stratification in diagnostically ambiguous cases of mediastinal lymphadenopathy.
After completing my specialist respiratory training in London, I worked as a consultant respiratory physician in Glasgow, before returning to UCL with an MRC Clinician Scientist Fellowship. I integrated a human in vivo mycobacterial challenge model with genetic manipulation of zebrafish larvae for mechanistic studies, to investigate immune correlates of disease severity in pulmonary TB. My work identified a potential host protective role for type I interferon responses in mycobacterial infection, with applications for risk-stratification of adverse outcomes and development of a novel host-directed therapy to mitigate against severe disease.
I also recently led a collaborative project funded by my NIHR UCLH Biomedical Research Centre Grant, to compare single-cell transcriptomic and T cell receptor profiles of bronchoalveolar cells from individuals with post-COVID radiological lung inflammation or fibrosis. Our findings implicate T cell driven immunopathology in post-COVID lung disease.
- Qualifications
-
- FRCP
- CCT Respiratory medicine and general medicine
- PhD Immunology
- MRCP (UK)
- MBChB
- BSc (Hons) Pathology
- Research interests
-
I have an established track record in research focused on understanding the immune correlates of protection and pathogenesis in respiratory infection and inflammation, particularly tuberculosis (TB). Ultimately my work aims to identify immune pathways that could be targeted for novel host-directed therapies to mitigate against the chronic sequelae of tissue injury and against anti-microbial resistance, stratify individuals likely to benefit from such interventions and inform design and evaluation of new vaccines.
I combine transcriptomic profiling of immune responses from human challenge and clinical samples, with genetic manipulation of zebrafish larval bacterial and sterile inflammation models to improve understanding of how to generate host responses that protect without immune-mediated pathology.
I pioneered transcriptomic profiling of biopsies from the site of the tuberculin skin test (TST) for comprehensive systems and molecular level interrogation of integrated innate and adaptive immune responses to Mycobacterium tuberculosis. My MRC Clinician Scientist Fellowship integrated my human in vivo mycobacterial challenge model, as a surrogate for immune responses to M. tuberculosis in the lung, with mechanistic studies in the zebrafish larval Mycobacterium marinum infection model, to investigate immune correlates of disease severity in pulmonary TB. The zebrafish mycobacterial infection model provides a natural host-pathogen interaction with granulomatous inflammation consistent with human TB. Zebrafish larvae are genetically tractable, which allows me to manipulate levels of genes to be tested, and optically transparent, enabling visualisation of bacterial growth and cellular responses to infection. This work identified type I interferon responses as host protective in mycobacterial infection, with implications for adjunctive type I interferon therapy to mitigate against severe disease in people with pulmonary TB
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- . eLife, 13.
- . Cell Reports Medicine, 3(3), 100557-100557.
- . Science Translational Medicine, 13(592).
- . Thorax, 76(4), 396-398.
- . Scientific Reports, 10(1).
- . Chest, 149(2), 535-544.
- . The Journal of Immunology, 193(7), 3736-3745.
- . The Journal of Infectious Diseases, 209(7), 1055-1065.
- . European Journal of Immunology, 41(11), 3253-3260.
- . Frontiers in Immunology, 15.
- . PLOS Pathogens, 15(12), e1008006-e1008006.
- . PLOS Pathogens, 12(3), e1005469-e1005469.
- . PLOS Pathogens, 11(4), e1004754-e1004754.
- . PLoS ONE, 7(6), e40348-e40348.
Preprints
All publications
Journal articles
- . eLife, 13.
- . Immunology, 167(3), 413-427.
- . Cell Reports Medicine, 3(3), 100557-100557.
- . Science Translational Medicine, 13(592).
- . Thorax, 76(4), 396-398.
- . Scientific Reports, 10(1).
- . mBio, 10(5).
- . Chest, 149(2), 535-544.
- . Thorax, 69(Suppl 2), A47-A47.
- . The Journal of Immunology, 193(7), 3736-3745.
- . The Journal of Infectious Diseases, 209(7), 1055-1065.
- . Thorax, 68(Suppl 3), A21.1-A21.
- . Thorax, 66(Suppl 4), A59-A60.
- . European Journal of Immunology, 41(11), 3253-3260.
- . Thorax, 65(Suppl 4), A4-A4.
- . Thorax, 65(Suppl 4), A37-A37.
- . Neuropathology and Applied Neurobiology, 29(4), 378-388.
- . Neuropathology and Applied Neurobiology, 25(5), 369-379.
- . Resuscitation, 41(2), 101-104.
- . Pathology, 31(1), 12-16.
- . Frontiers in Immunology, 15.
- . PLOS Pathogens, 15(12), e1008006-e1008006.
- . F1000Research, 7, 217-217.
- . PLOS Pathogens, 12(3), e1005469-e1005469.
- . PLOS Pathogens, 11(4), e1004754-e1004754.
- . PLoS ONE, 7(6), e40348-e40348.
Conference proceedings papers
- . 鈥楤ad blood鈥 鈥 Biomarkers and mechanisms in long COVID (pp A61-A61)
- . Mechanisms of lung injury and repair (pp OA1566-OA1566)
- . 10.1 Respiratory Infections (pp PA2672-PA2672)
- . D21. GENETICS OF AIRWAY DISEASES II (pp A5425-A5425)
- . D21. GENETICS OF AIRWAY DISEASES II (pp A5439-A5439)
Preprints
- Grants
-
Medical Research Council Clinician Scientist Fellowship (2016-2024)
Tuning the immune response in tuberculosisNIHR University College London Hospitals Biomedical Research Centre Inflammation, Immunity and Immunotherapeutics Theme (2020-2022)
Immune pathogenesis of post-COVID-19 lung disease
- Teaching interests
-
I have previously used my expertise in respiratory infection and immunology to lecture on Immunology Masters and undergraduate courses to deliver researcher-led teaching
- Professional activities and memberships
-
- British Thoracic Society member.
- British Society for Immunology member.
- European Respiratory Society member.
- Peer reviewer of manuscripts and grants.